Eshe Nelson

Eshe Nelson, an economics and business reporter for The New York Times based in London, dives into the transformation of GLP-1 drugs like Ozempic and Wegovy. She discusses the upcoming pricing changes that promise broader access, stemming from a significant agreement struck with pharmaceutical companies during the Trump administration. The conversation also covers how Ozempic evolved from a diabetes drug to a weight-loss sensation, and the ensuing supply challenges faced by its maker, Novo Nordisk, amid skyrocketing demand.